Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors

The achievement of a 3‐month complete molecular response (CMR) is a major prognostic factor for survival in patients with Philadelphia chromosome (Ph)‐positive acute lymphoblastic leukemia (ALL). However, 25% of patients relapse during therapy with tyrosine kinase inhibitors (TKIs).

[1]  H. Kantarjian,et al.  Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management , 2019, Cancer.

[2]  M. Konopleva,et al.  Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia , 2019, Blood.

[3]  M. Konopleva,et al.  Poor outcomes associated with +der(22)t(9;22) and −9/9p in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor , 2017, American journal of hematology/oncology.

[4]  N. Kanitsap,et al.  Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosomepositive ALL. , 2016 .

[5]  J. Radich,et al.  US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. , 2016, Blood advances.

[6]  J. Cayuela,et al.  Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. , 2016, Blood.

[7]  G. Garcia-Manero,et al.  Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2016, Blood.

[8]  Z. Estrov,et al.  Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia , 2015, Cancer.

[9]  J. Cayuela,et al.  Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. , 2015, Blood.

[10]  M. Konopleva,et al.  Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia , 2015, Haematologica.

[11]  M. Tallman,et al.  UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. , 2014, Blood.

[12]  C. Bloomfield,et al.  Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance) , 2014, Haematologica.

[13]  I. Flinn,et al.  Ponatinib in refractory Philadelphia chromosome-positive leukemias. , 2012, The New England journal of medicine.

[14]  R. Foà,et al.  Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2011, Blood.

[15]  H. Kantarjian,et al.  First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. , 2010, Blood.

[16]  R. Larson,et al.  Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study , 2010, American journal of hematology.

[17]  S. Mustjoki,et al.  Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome‐positive acute lymphoblastic leukaemia , 2009, British journal of haematology.

[18]  J. Radich,et al.  Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. , 2007, Blood.

[19]  U. Dührsen,et al.  Imatinib compared with chemotherapy as front‐line treatment of elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL) , 2007, Cancer.

[20]  H. Gschaidmeier,et al.  Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). , 2006, Blood.

[21]  H. Dombret,et al.  Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study , 2006, Leukemia.

[22]  M. Andreeff,et al.  Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. , 2004, Blood.

[23]  Zhong Li-ye.  Imatinib Compared with Chemotherapy as Front-Line Treatment of Elderly Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) , 2009 .

[24]  L. Medeiros,et al.  TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type , 2004, Modern Pathology.